Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,620.00
Bid: 1,619.50
Ask: 1,620.00
Change: -20.00 (-1.22%)
Spread: 0.50 (0.031%)
Open: 1,633.00
High: 1,641.00
Low: 1,616.00
Prev. Close: 1,640.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

12 Sep 2017 16:07

RNS Number : 5501Q
GlaxoSmithKline PLC
12 September 2017
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

   

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

   

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.0052

8 (partnership shares)

£15.0052

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.0052

 

 

e)

Date of the transaction

2017-09-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHELLFFDKFBBBE
Date   Source Headline
13th Jan 202010:34 amRNSDirector/PDMR Shareholding
8th Jan 20204:30 pmRNSGSK publishes provisional 2020 Dividend Dates
8th Jan 20203:11 pmRNSGSK publishes 2020 Dividend Dates
8th Jan 20202:37 pmRNSGSK Announces addition to Corporate Executive Team
2nd Jan 20209:58 amRNSTotal Voting Rights
23rd Dec 20197:01 amRNSViiV Healthcare receives complete response letter
18th Dec 20195:12 pmRNSDirector/PDMR Shareholding
18th Dec 20194:55 pmRNSDirector/PDMR Shareholding
17th Dec 20199:00 amRNSBlocklisting Application
13th Dec 20194:48 pmRNSDirector/PDMR Shareholding
11th Dec 20194:57 pmRNSDirector/PDMR Shareholding
5th Dec 201912:00 pmRNSViiV submits NDA to FDA for fostemsavir
4th Dec 20195:34 pmRNSEmma Walmsley - External Appointment
2nd Dec 20195:52 pmRNSDirector/PDMR Shareholding
2nd Dec 20194:54 pmRNSTotal Voting Rights
26th Nov 20193:00 pmRNSBlock listing Interim Review
12th Nov 20193:51 pmRNSDirector/PDMR Shareholding
8th Nov 20194:22 pmRNSDirector/PDMR Shareholding
6th Nov 20194:36 pmRNSDirector/PDMR Shareholding
4th Nov 20195:35 pmRNSDirector/PDMR Shareholding
1st Nov 20195:19 pmRNSDirector/PDMR Shareholding
1st Nov 20199:53 amRNSTotal Voting Rights
31st Oct 20191:34 pmRNSDirector/PDMR Shareholding
30th Oct 20195:32 pmRNSDirector/PDMR Shareholding
30th Oct 201912:07 pmRNSSecond Price Monitoring Extn
30th Oct 201912:02 pmRNSPrice Monitoring Extension
30th Oct 201912:00 pmRNS3rd Quarter Results
21st Oct 20198:00 amRNSGSK divests two travel vaccines to Bavarian Nordic
15th Oct 20195:00 pmRNSDirector/PDMR Shareholding
15th Oct 20195:00 pmRNSDirector/PDMR Shareholding
15th Oct 20195:00 pmRNSDirector/PDMR Shareholding
15th Oct 20195:00 pmRNSDirector/PDMR Shareholding
11th Oct 20195:34 pmRNSDirector/PDMR Shareholding
11th Oct 20194:10 pmRNSDirector/PDMR Shareholding
10th Oct 20194:18 pmRNSDirector/PDMR Shareholding
1st Oct 20196:18 pmRNSDirector/PDMR Shareholding
1st Oct 20191:09 pmRNSTotal Voting Rights
30th Sep 20197:00 amRNSPRIMA shows Zejula improves PFS in ovarian cancer
30th Sep 20197:00 amRNSData show anti-tumour activity with ICOS agonist
26th Sep 20196:26 pmRNSDirector/PDMR Shareholding
17th Sep 20195:46 pmRNSDirector/PDMR Shareholding
11th Sep 20194:30 pmRNSDirector/PDMR Shareholding
4th Sep 20195:37 pmRNSDirector/PDMR Shareholding
4th Sep 201912:36 pmRNSDirector/PDMR Shareholding
4th Sep 20199:33 amRNSDirector/PDMR Shareholding
2nd Sep 201911:29 amRNSTotal Voting Rights
23rd Aug 20197:00 amRNSGSK - positive results from pivotal DREAMM-2 study
22nd Aug 20197:00 amRNSViiV results positive for every 2 month injection
21st Aug 20198:00 amRNSGSK submits regulatory file in Japan: Daprodustat
12th Aug 20193:45 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.